GlassScriptPhysician profile
James A Sattler
NPI 1982693164
$5,139.61
in general payments reported to CMS, 2019-2025
23 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $262 · 2021: $477 · 2022: $788 · 2023: $580 · 2024: $885 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Travel and Lodging: $555 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.20 |
| Travel and Lodging | $554.93 |
| Education | $278.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,161.01 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,061.51 | 2019-2025 | Skyrizi, Rinvoq |
| Endogastric Solutions, INC | $438.79 | 2019-2024 | Esophyx |
| Gilead Sciences, INC. | $415.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $345.69 | 2021-2022 | |
| Pfizer INC. | $345.10 | 2019-2025 | |
| Boston Scientific Corporation | $314.21 | 2019-2022 | |
| Celgene Corporation | $234.81 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $179.92 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $116.50 | 2021-2022 | |
| Romark Laboratories, Lc | $112.26 | 2019-2020 | |
| Merit Medical Systems INC | $80.99 | 2025 | Esophyx |
| Teleflex LLC | $66.66 | 2019 | |
| Amgen INC. | $61.13 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $36.32 | 2024-2025 | Iqirvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3-D Matrix, INC. | $29.74 | 2024 | |
| Nestle Healthcare Nutrition INC. | $23.12 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.05 | 2025 | Rebyota |
| Qol Medical, LLC | $20.70 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.42 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $20.12 | 2025 | Sutab, Suflave |
| Celltrion USA INC. | $17.52 | 2025 | Vegzelma |
| Genzyme Corporation | $16.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sattler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.